This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kastan, M. B. Articles by Craig, R. W. Search for Related Content PubMed PubMed Citation Articles by Kastan, M. B. Articles by Craig, R. W.

Levels of p53 Protein Increase with Maturation in Human Hematopoietic Cells¹

The Johns Hopkins Oncology Center [M. B. K., A. I. R., S. J. K., O. O., C. I. C., K. D. S., T. W.] and Department of Physiology [C. A. W., R. W. C.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and The Wayne State University School of Medicine, Detroit, Michigan 48202 [Y. R.]

Transfection of the wild-type p53 gene into malignant cell lines usually results in an inhibition of proliferation. However, the physiological function of the endogenous p53 gene product has been difficult to ascertain. In order to examine whether p53 is involved in the regulation of proliferation and/or differentiation of hematopoietic tissue, we modified a recently developed flow cytometric assay to assess p53 protein expression in normal human hematopoietic cells, primary leukemias, and selected leukemia cell lines. In normal human bone marrow, p53 protein was not detected in the proliferative, progenitor cell populations identified by the cell surface antigens CD34 (progenitor cells of multiple lineages) or glycophorin (erythroid precursors). In contrast, low but detectable levels of p53 protein were observed in the nonproliferative, mature lymphoid, granulocytic, and monocytic cell populations. Similarly, p53 levels increased and DNA synthesis decreased during 12-O-tetradecanoylphorbol-13-acetate-induced differentiation of ML-1 myeloblastic leukemia cells. Both of these results suggest that endogenous, wild-type p53 protein may play a role in hematopoietic cell maturation, possibly by contributing to the inhibition of proliferation that occurs during terminal differentiation. Leukemia cells deviated from this pattern of expression: (a) in contrast to the normal, proliferative bone marrow progenitor cells, a significant percentage of patient leukemia samples expressed detectable levels of p53 protein; and (b) leukemia cell lines exhibited lineage-specific abnormalities in p53 expression, with overexpression in lymphoid cell lines and lack of expression in myeloid cell lines.

¹ This work was supported in part by grants from the American Cancer Society (CD-434, CH-480, and Maryland Division). M. B. K. is a Scholar of the Children's Cancer Foundation and a W. M. Keck Foundation Scholar. Presented in part at the 1990 meeting of the American Society of Hematology.

² To whom requests for reprints should be addressed, at Oncology 3-120, Johns Hopkins Hospital, 600 N. Wolfe St., Baltimore, MD 21205.

Received 4/11/91. Accepted 5/30/91.

This article has been cited by other articles:

				E. Grinstein, Y. Du, S. Santourlidis, J. Christ, M. Uhrberg, and P. Wernet Nucleolin Regulates Gene Expression in CD34-positive Hematopoietic Cells J. Biol. Chem., April 27, 2007; 282(17): 12439 - 12449. [Abstract] [Full Text] [PDF]

				D. Dornan, H. Shimizu, A. Mah, T. Dudhela, M. Eby, K. O'Rourke, S. Seshagiri, and V. M. Dixit ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science, August 25, 2006; 313(5790): 1122 - 1126. [Abstract] [Full Text] [PDF]

				T. Abbas, D. White, L. Hui, K. Yoshida, D. A. Foster, and J. Bargonetti Inhibition of Human p53 Basal Transcription by Down-regulation of Protein Kinase C{delta} J. Biol. Chem., March 12, 2004; 279(11): 9970 - 9977. [Abstract] [Full Text] [PDF]

				J. Gong, S. Ammanamanchi, T. C. Ko, and M. G. Brattain Transforming Growth Factor {beta}1 Increases the Stability of p21/WAF1/CIP1 Protein and Inhibits CDK2 Kinase Activity in Human Colon Carcinoma FET Cells Cancer Res., June 15, 2003; 63(12): 3340 - 3346. [Abstract] [Full Text] [PDF]

				S. Strudwick, L. M. Carastro, T. Stagg, and P. Lazarus Differential Transcription-Coupled Translational Inhibition of Human p53 Expression: A Potentially Important Mechanism of Regulating p53 Expression in Normal versus Tumor Tissue Mol. Cancer Res., April 1, 2003; 1(6): 463 - 474. [Abstract] [Full Text] [PDF]

				L. Ji, M. Nishizaki, B. Gao, D. Burbee, M. Kondo, C. Kamibayashi, K. Xu, N. Yen, E. N. Atkinson, B. Fang, et al. Expression of Several Genes in the Human Chromosome 3p21.3 Homozygous Deletion Region by an Adenovirus Vector Results in Tumor Suppressor Activities in Vitro and in Vivo Cancer Res., May 1, 2002; 62(9): 2715 - 2720. [Abstract] [Full Text] [PDF]

				E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur. Respir. J., October 1, 2001; 18(4): 705 - 719. [Abstract] [Full Text] [PDF]

				R. Fishel The Selection for Mismatch Repair Defects in Hereditary Nonpolyposis Colorectal Cancer: Revising the Mutator Hypothesis Cancer Res., October 1, 2001; 61(20): 7369 - 7374. [Full Text] [PDF]

				D. H. Christiansen, M. K. Andersen, and J. Pedersen-Bjergaard Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis J. Clin. Oncol., March 1, 2001; 19(5): 1405 - 1413. [Abstract] [Full Text] [PDF]

				M.-L. Li, L. Horn, P. S. Firby, and M. J. Moore Pharmacological Determinants of 9-Aminocamptothecin Cytotoxicity Clin. Cancer Res., January 1, 2001; 7(1): 168 - 174. [Abstract] [Full Text]

				A. Porrello, M. A. Cerone, S. Coen, A. Gurtner, G. Fontemaggi, L. Cimino, G. Piaggio, A. Sacchi, and S. Soddu p53 Regulates Myogenesis by Triggering the Differentiation Activity of pRb J. Cell Biol., December 11, 2000; 151(6): 1295 - 1304. [Abstract] [Full Text] [PDF]

				K. Maki, K. Mitani, T. Yamagata, M. Kurokawa, Y. Kanda, Y. Yazaki, and H. Hirai Transcriptional Inhibition of p53 by the MLL/MEN Chimeric Protein Found in Myeloid Leukemia Blood, May 15, 1999; 93(10): 3216 - 3224. [Abstract] [Full Text] [PDF]

				P. Ruiz-Lozano, M. L. Hixon, M. W. Wagner, A. I. Flores, S. Ikawa, A. S. Baldwin Jr., K. R. Chien, and A. Gualberto p53 Is a Transcriptional Activator of the Muscle-specific Phosphoglycerate Mutase Gene and Contributesin Vivo to the Control of Its Cardiac Expression Cell Growth Differ., May 1, 1999; 10(5): 295 - 306. [Abstract] [Full Text]

				P. Wlodarski, M. Wasik, M. Z. Ratajczak, C. Sevignani, G. Hoser, J. Kawiak, A. M. Gewirtz, B. Calabretta, and T. Skorski Role of p53 in Hematopoietic Recovery After Cytotoxic Treatment Blood, April 15, 1998; 91(8): 2998 - 3006. [Abstract] [Full Text] [PDF]

				C. A. Hsu, A. K. Rishi, X. Su-Li, T. M. Gerald, M. I. Dawson, C. Schiffer, U. Reichert, B. Shroot, G. C. Poirer, and J. A. Fontana Retinoid Induced Apoptosis in Leukemia Cells Through a Retinoic Acid Nuclear Receptor-Independent Pathway Blood, June 15, 1997; 89(12): 4470 - 4479. [Abstract] [Full Text] [PDF]